Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

July

25

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and...

4

electroCore Announces Record Second Quarter 2022 Financial Results

Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and...

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021 June...

12

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021...

12

gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)

nVNS reduces symptoms of PTSD by 31% in sham-controlled study ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE...

14

electroCore, Inc. Provides Update on nVNS to Treat Post Traumatic Stress Disorder

ROCKAWAY, NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic...

10

Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress

Peer-reviewed manuscript reports results of study conducted at Georgia Tech and Emory, funded in...

5

electroCore Announces Second Quarter 2021 Financial Results

Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020...

27

electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)

Double-blind sham-controlled study of nineteen participants who had experienced trauma but did not have...

Recent developments

News

July

25

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

August

4

electroCore Announces Record Second Quarter 2022 Financial Results

July

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

April

12

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

January

12

gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)

December

14

electroCore, Inc. Provides Update on nVNS to Treat Post Traumatic Stress Disorder

August

10

Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress

August

5

electroCore Announces Second Quarter 2021 Financial Results

August

27

electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)